New York, NY (PRWEB) August 21, 2014
Medivo, Inc., a leader in lab data and healthcare analytics, has appointed clinical lab industry leader David W. Bryant to its Advisory Board, which represents a panel of recognized leaders in the life science and health information technology sectors who provide strategic guidance to the company.
Mr. Bryant is the former chief executive officer of Sonic Healthcare USA, the third-largest clinical laboratory operation in the United States, and also the former chief executive officer of CBLPath Inc., a medical lab that provides anatomic pathology and molecular diagnostic laboratory services. (Sonic Healthcare USA acquired CBLPath in 2010.)
“We are extremely pleased to add David and his leadership experience in the lab industry to our Advisory Board,” said Sundeep Bhan, Chief Executive Officer and a Co-Founder of Medivo. “His expertise in leading Sonic Healthcare USA and other clinical laboratory businesses will enable Medivo to develop new insights that enhance our proprietary Lab Value Exchange(TM) database and also allow us to be more innovative in the ways we’re helping life science companies leverage new data to inform their commercialization strategies.”
Mr. Bryant joins Medivo’s Advisory board effective August 2014.
“It’s an honor to join the Medivo team in this important advisory role,” Mr. Bryant said. “I am very familiar with the innovative ideas that Medivo is developing around healthcare data analytics and I look forward to working with its exceptional team of advisors as the company builds out the Medivo LVX platform.”
The Medivo Lab Value Exchange (LVX(TM)) is the largest aggregation of standardized and anonymized lab test results available in the market today, and contains data from 140+ U.S. labs with data across 200,000 practice locations and 29 million patients.
About Medivo’s Advisory Board
Medivo established its Advisory Board in 2010 to provide strategic advice and counsel in the areas of health information technology, data analytics, commercialization strategies and financial planning. Members who comprise the board are:
Medivo unlocks the power of lab data to better inform treatment decisions and improve health outcomes. Medivo’s data analysts and clinical experts extract proprietary insights from the Medivo Lab Value ExchangeTM (LVXTM), a network of more than 140 U.S. labs with data across 200,000 practice locations and 29 million patients. These insights enable life science companies to build intelligent profiling knowledge, to make proactive decisions and to optimize their sales and marketing initiatives. Medivo’s services also enable physicians to better track and improve outcomes, and its Lab partners to realize the full value of their data assets. Founded in 2010 by healthcare entrepreneurs, Medivo’s investors include Safeguard Scientifics, Inc. (NYSE:SFE) and Merck Global Health Innovation Fund (GHIF). For more information, visit http://www.medivo.com.